Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

It seems to be holding off on price adjustments demanded by President Trump.

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.